No Data
No Data
Silo Pharma's SP-26 Implant Shows Early Results in Chronic Pain and Fibromyalgia Study
Express News | Silo Pharma Inc - Final Safety and Absorption Data Expected in March 2025
Express News | Silo Pharma Inc - No Serious Side Effects Observed in SP-26 Study
Express News | Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia
Silo Pharma Announces Provisional Patent Filing For SPC-15 Targeting NMDARs And 5-HT4Rs For Stress-Induced Psychiatric Disorders; Advances Collaboration With Columbia University
Silo Pharma Advances Intellectual Property Portfolio With Provisional Patent Filing for PTSD Treatment